Biomedical Engineering Reference
In-Depth Information
68. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M,
MGMT gene silencing and benefit from temozolomide in glioblastoma.
N Engl J Med
et al.
2005 Mar 10; 352(10): 997-1003.
69. Zhang YW, Regairaz M, Seiler JA, Agama KK, Doroshow JH, Pommier
Y. Poly(ADP-ribose) polymerase and XPF-ERCC1 participate in distinct
pathways for the repair of topoisomerase I-induced DNA damage in
mammalian cells.
2011 May; 39(9): 3607-3620.
70. Smith LM, Willmore E, Austin CA, Curtin NJ. The novel poly(ADP-Ribose)
polymerase inhibitor, AG14361, sensitizes cells to topoisomerase
I poisons by increasing the persistence of DNA strand breaks.
Nucleic Acids Res
Clin
2005 Dec 1; 11(23): 8449-8457.
71. Donawho CK, Luo Y, Penning TD, Bauch JL, Bouska JJ, Bontcheva-Diaz
VD,
Cancer Res
ABT-888, an orally active poly(ADP-ribose) polymerase
inhibitor that potentiates DNA-damaging agents in preclinical tumor
models.
et al.
2007 May 1; 13(9): 2728-2737.
72. Burkle A, Chen G, Kupper JH, Grube K, Zeller WJ. Increased poly(ADP-
ribosyl)ation in intact cells by cisplatin treatment.
Clin Cancer Res
Carcinogenesis
1993
Apr; 14(4): 559-561.
73. Miknyoczki SJ, Jones-Bolin S, Pritchard S, Hunter K, Zhao H, Wan W,
et al.
Chemopotentiation of temozolomide, irinotecan, and cisplatin
activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor.
Mol
2003 Apr; 2(4): 371-382.
74. Calabrese CR, Almassy R, Barton S, Batey MA, Calvert AH, Canan-Koch
S,
Cancer Ther
Anticancer chemosensitization and radiosensitization by the
novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.
et al.
J Natl Cancer
2004 Jan 7; 96(1): 56-67.
75. Rajan A. A Phase I Combination Study of Olaparib (AZD 2208; KU-
0059436) and Cisplatin Plus Gemcitabine in Adults With Solid Tumors.
TAT [abstract]. 2010.
76. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M,
Inst
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA
mutation carriers.
et al.
2009 Jul 9; 361(2): 123-134.
77. Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley
C,
N Engl J Med
Poly(ADP)-ribose polymerase inhibition: frequent durable
responses in BRCA carrier ovarian cancer correlating with platinum-
free interval.
et al.
2010 May 20; 28(15): 2512-2519.
78. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-
McGuinn KM,
J Clin Oncol
Oral poly(ADP-ribose) polymerase inhibitor
olaparib in patients with BRCA1 or BRCA2 mutations and recurrent
et al.
